2018 Global Endometriosis Strategic Business Report - Developing Regions Exhibit Immense Growth Potential

DUBLIN, Feb. 20, 2018 /PRNewswire/ --

The "Endometriosis - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022.

Also, a six-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. The report analyzes the worldwide markets for Endometriosis in US$ Million.

The report profiles 38 companies including many key and niche players such as:

• AbbVie Inc. (US)
• AEterna Zentaris Inc. (Canada)
• Astellas Pharma Inc. (Japan)
• AstraZeneca Plc. (UK)
• Bayer HealthCare Pharmaceuticals, Inc. (US)
• Debiopharm Group (Switzerland)
• Evotec AG (Germany)
• Kissei Pharmaceutical Co., Ltd. (Japan)
• Neurocrine Biosciences, Inc. (US)
• ObsEva SA (Switzerland)
• Pfizer, Inc. (US)
• Repros Therapeutics, Inc. (US)
• Roivant Sciences Ltd. (US)
• Takeda Pharmaceutical Company Limited (Japan)
• ValiRx Plc (UK)

Key Topics Covered:

I. Introduction, Methodology & Product Definitions
Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study

II. Executive Summary

1. Industry Overview
Endometriosis: An Introductory Prelude
Endometriosis Facts in a Nutshell
Poor Efficacy & Safety Profiles of Existing Drugs Lead to Unmet Medical Needs
Key Endometriosis Drugs on the Market
The Pipeline Review
Key Endometriosis Drugs in the Pipeline: 2017
Steady Growth Expected Over the Next Few Years
Emerging Treatment for Endometriosis & Endometrial Cancer
Global Awareness Campaigns and Efforts
Uptrend in Healthcare Expenditure Creates Substantial Opportunities
Developed Regions Remain Primary Revenue Contributors
Developing Regions Exhibit Immense Growth Potential
Stable Economic Scenario to Augment Market Prospects

2. Endometriosis & Its Treatment - An Overview
Introduction
Occurrence of Endometriosis in Women
Causes and Symptoms
Causes
Estrogen Theory
Mllerianosis Theory
Retrograde Menstruation Theory
Coelomic Metaplasia Theory
Hereditary Factors
Environmental Factors
Dioxin Behavior in the Body
Birth Defects
Other Causes
Symptoms of Endometriosis
Reasons for Pain due to Endometriosis
Endometriosis and Infertility
Kinds of Endometriosis
Reproductive Area Endometriosis
Uterosacral/Presacral Nerve Endometriosis
Cul-de-Sac ("Pouch of Douglas") Endometriosis
Gastrointestinal Endometriosis
Pleural (lung/chest cavity/diaphragmatic) Endometriosis
Urinary Tract (kidneys, ureters, bladder and urethra) Endometriosis
Skin Endometriosis
Sciatic Endometriosis
Stages of Endometriosis
Diagnosis of Endometriosis
Major Diagnostic Techniques
Pelvic Exam
Laparoscopy
Other Diagnostic Procedures
A New Non-invasive Test for the Diagnosis of Endometriosis
Endometriosis Markers
Counseling of patients
Recurrence of Endometriosis
Endometriosis & Infertility
Miscarriage
Endometriosis & Thyroid Autoimmunity
Relationship between Endometriosis and Autoimmune Disease
Endometriosis & Cancer
Associations & Research Centers
The Endometriosis Association
Endometriosis Research Center

3. Treatment of Endometriosis
Endometriosis & Available Treatment Options
Endometriosis Treatment Mechanisms: In a Nutshell
I. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
II. Hormonal Therapy
Gonadotropin Releasing Hormone (Gnrh) Agonists
Select Major GnRH-Agonists for Endometriosis Treatment
Lupron, Zoladex and Synarel
The Major Drugs
AbbVie's Lupron (Leuprorelin)
AstraZeneca's Zoladex (Goserelin)
Pfizer's Synarel (Nafarelin Acetate)
Add-back Medication
Progestogens
Select Major Progestins for Endometriosis Treatment
Combined Oral Contraceptive Pill
Danazol and Other Suppressive Steroids
Chinese Herbs
More Effective than Danazol or Gestrinone
Aromatase Inhibitors
III. Non-hormonal Therapy
Anti-Angiogenic Agents
Selective COX-2 Inhibitors
TNF-Alpha Inhibitors
IV. Surgical Techniques
V. Complementary Therapies
Long-term Approach to Pain
Lifestyle Modifications
Chinese Herbs
Treatment for Endometriosis-related Infertility
Hormonal Treatment
Minimal to Mild Endometriosis
Moderate-Severe Endometriosis
Surgical Treatment
Minimal-Mild Endometriosis
Moderate-Severe Endometriosis
Treatment for Ovarian Endometriosis
Surgical Vs. Medicinal Interventions
Medicinal Interventions
Advantages
Disadvantages
Surgery
Advantages
Disadvantages
In-vitro Fertilization
Other Treatment

4. Select Clinical Trials/Product Innovations & Approvals
AbbVie and Neurocrine Bag US FDA Priority Review Clearance for Elagolix
AbbVie Announces Results from Replicate Phase 3 Extension Studies for Elagolix
Bayer Commences Enrolling Patients for Phase III Program to Study Vilaprisan's Efficacy in Treating Symptomatic UF
ObsEva to Commence Phase 2b EDELWEISS Clinical Trial of OBE2109
Repros Keeps Proellex Development Program on Partial Clinical Hold of FDA
Aeterna Zentaris Halts Development of Zoptrex
Evotec and Bayer's Endometriosis Alliance Portfolio Advances into Phase I Clinical Development
ObsEva Commences Phase 3 Clinical Program to Evaluate OBE2109 to Treat UF
Myovant Achieves Positive Phase 3 Study Results for Relugolix in Treating UF
Myovant Commences Phase 3 Program of Relugolix for Treating Endometriosis-Associated Pain
Repros Therapeutics' Achieves Positive Results from Proellex Phase II Study
ValiRx Bags European Patent for VAL201
Virexxa Receives FDA Clearance to Proceed to Phase II
OBE2109 by ObsEva Receives IND Clearance
Galena Biopharma Presents Phase 1/2a Data on Endometrial Cancer Immunotherapies
AbbVie and Neurocrine Report Positive Phase 3 Trial Data of Elagolix
ValiRx Plc to Begin Endometriosis Clinical Research with its VAL201
Aurobindo Pharma Receives FDA Approval to Market Tablets for Endometriosis Treatment
Lumenis to Introduce UltraPulse DUO CO2 laser system and FemTouch Solution
Bayer Launches Phase II Trials of vilaprisan for Endometriosis Treatment
Nippon Shinyaku Conducts Phase I Evaluation of NS 580 for Endometriosis Therapy
Teleflex to Showcase its Surgical Solutions for Endometriosis
ValiRx Plc Receives Patent Grant for VAL201

5. Recent Industry Activity
AstraZeneca Bags Commercial Rights to Zoladex
Astellas Pharma to Acquire Ogeda
Roivant Establishes New Global Headquarters in Basel
Takeda and Roivant Partner to Form Myovant
Evotec-Bayer Collaboration Reaches Important Clinical Milestones for Endometriosis Therapy
ObsEva and Kissei Pharmaceutical Enter Into Collaboration Agreement for KLH-2109

6. Focus on Select Global Players

7. Global Market Perspective

Total Companies Profiled: 38 (including Divisions/Subsidiaries 40)

The United States (11)
Canada (3)
Japan (6)
Europe (15)
- France (1)
- Germany (3)
- The United Kingdom (2)
- Rest of Europe (9)
Asia-Pacific (Excluding Japan) (3)
Middle East (1)
Latin America (1)

For more information about this report visit https://www.researchandmarkets.com/research/skjdrj/2018_global?w=5

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

Related Links

http://www.researchandmarkets.com